Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75368
UPID:
SH3L1_HUMAN
Alternative names:
SH3 domain-binding glutamic acid-rich-like protein 1
Alternative UPACC:
O75368; Q3SYL1; Q5JT50; Q6FIE8; Q9H0N8
Background:
Adapter SH3BGRL, also known as SH3 domain-binding glutamic acid-rich-like protein 1, plays a crucial role in cellular processes. It acts as an adapter protein, facilitating interactions between proteins or proteins and mRNAs, as evidenced by research findings (PubMed:34331014). Furthermore, SH3BGRL is implicated in ubiquitin ligase-substrate adapter activity and associates with cytoplasmic ribosomes to enhance the expression of specific mRNAs (PubMed:34331014, PubMed:34870550).
Therapeutic significance:
Understanding the role of Adapter SH3BGRL could open doors to potential therapeutic strategies.